Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

doi:10.1016/S0168-8278(05)80657-9

Journal of Hepatology

Volume 16, Issue 3, 1992, Pages 273-281

https://doi.org/10.1016/S0168-8278(05)80657-9 Get rights and content

Abstract

One hundred and thirty-five patients who developed non-A, non-B post-transfusion hepatitis mostly after cardiac surgery, were followed for a mean (±S.D.) of 90±41 months (range: 13–180) to evaluate clinical and histological outcome.

Thirty-one cases resolved within 12 months, while 104 (77%) progressed to chronicity. Twenty-one of 65 (32%) biopsied patients developed cirrhosis at the end of the follow-up, and one further progressed to hepatocellular carcinoma. One patient had a complete histological remission (1%). The remaining cases had chronic active (37%), chronic persistent (27%) or chronic lobular hepatitis (3%). About half of the cases with cirrhosis developed portal hypertension, and three of these died due to esophageal varices hemorrhage, one due to liver failure, and one due to hepatocellular carcinoma. Out of 26 patients with the initial histologic diagnosis of chronic hepatitis that were rebiopsied during follow-up, 13 (50%) progressed to cirrhosis. These patients were significantly older than patients who did not develop cirrhosis (mean age 57 and 45 years respectively; p<0.01).

During acute hepatitis anti-HCV was positive in all but one of the 114 patients tested. Percentages were similar for patients who recovered (95%) and those who developed chronic hepatitis (100%). However, during follow-up, 71% of the 1st generation and 21% of the 2nd generation ELISA test patients with acute resolved hepatitis became anti-HCV negative, while the same figures in chronic cases were only 8.5% (p<0.0001) and 1.4% (p=0.012). This suggests a correlation between anti-HCV antibody activity, hepatitis C virus replication, and the development of chronic liver disease.

References (30)

KnodellRG et al.
Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis
Lancet
(1976)
Van der PoelCL et al.
Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay
Lancet
(1991)
KoretzRL et al.
The non-A, non-B post-transfusion hepatitis—a decade later
Gastroenterology
(1985)
HayCRM et al.
Progressive liver disease in haemophilia: an understated problem?
Lancet
(1985)
KnodellRG et al.
Development of chronic liver disease after acute non-A, non-B post-transfusion hepatitis
Gastroenterology
(1977)
WilliamsALB et al.
Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis
Gastroenterology
(1988)
RakelaJ et al.
Chronic liver disease after acute non-A, non-B viral hepatitis
Gastroenterology
(1979)
AachRD et al.
Transfusion-transmitted viruses: interim analysis of hepatitis among transfused and non-transfused patients
TremoladaF et al.
Prospective study of post-transfusion hepatitis in cardiac-surgery patients receiving only blood or also blood products
Vox Sang
(1983)
MattsonL
Chronic non-A, non-B hepatitis with special reference to the transfusion-associated form
Scand J Infect Dis
(1989)

ChooQL et al.

Isolation of cDNA clone derived from a blood-borne non-A, non-B hepatitis genome

Science

(1989)

KuoG et al.

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

Science

(1989)

ChooQ-L et al.

Hepatitis C virus: the major causative agent of viral non-A, nonB hepatitis

Br Med Bull

(1990)

EbelingF et al.

Post-transfusion hepatitis C in Finland

Transfus Med

(1991)

BermanM et al.

The chronic sequelae of non-A, non-B hepatitis

Ann Intern Med

(1979)

Cited by (275)

Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project
2022, Annals of Hepatology
In 1999, a population-based survey showed a 5.6 % (102/1832) prevalence of HCV infection in O'Brien, a small rural town of Argentina. The aim of this study was to assess the impact of screening, clinical evaluation and antiviral therapy on elimination of HCV after 20 years of follow-up.
HCV+ subjects (n=102) underwent clinical, biochemical and histological evaluation to assess the presence and severity of liver disease. Antiviral therapy included pegylated interferon + ribavirin in 2005 and direct antiviral agents from 2017.
All viremic subjects (n=84) had genotype 1b with 90%-97.5% sequence homology scores, suggesting the existence of a common source of infection (use of unsafe injections administered by the same health professional). Liver biopsy (n=55) showed chronic hepatitis in all patients. The prevalence of cirrhosis was 28% overall (29/102) and 34.5% among viremic patients. Sustained virological response (SVR) was obtained in 20/34 (59%) patients treated with interferon. From 2005 to 2017, when oral antivirals became available 37/50 untreated patients died. Median age of this group in 2005 was 67 years. Six interferon non-responders and five naive subjects received direct antiviral agents and all developed SVR. Only 1/31 patient (3.2%) with SVR died and none developed decompensated cirrhosis or HCC. In 2019, a new population-based study showed that the prevalence of HCV in O'Brien decreased 20-fold, from 5.6% to 0.28% (3/1070).
Despite the high mortality rate precluding timely access to direct antiviral agents, the O'Brien Project is a good example of HCV micro-elimination studies
Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in australia
2014, Value in Health
Protease inhibitors such as telaprevir (Incivo) are reimbursed in Australia for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection in combination with pegylated interferon and ribavirin (PR).
To assess the cost-effectiveness of telaprevir plus PR compared with PR alone in 1) previously untreated patients and 2) patients who had received treatment with PR earlier.
Sustained virological response rates and average treatment durations of telaprevir and PR (given with or without telaprevir) were taken from the telaprevir ADVANCE and REALIZE clinical trials but were modified to take account of differences in prescribing rules between the trials and Australian clinical practice. The probability of transitioning between Markov disease states was based on data from the Australian Kirby Institute where possible and supplemented using data from the published literature. Utility values obtained from the EuroQol five-dimensional questionnaire data collected in the ADVANCE and REALIZE trials were used to represent the utility during HCV treatment. Utility values for Markov health states were taken from the published literature. Unit costs (2014 AU $) were taken from Australian sources.
In treatment-naive patients, the discounted cost per life-years gained was AU $37,706 and the discounted cost per quality-adjusted life-year was AU $19,283. In treatment-experienced patients, the discounted cost per life-year gained was AU $23,855 and the discounted cost per quality-adjusted life-year was AU $14,948.
Telaprevir plus PR in the Australian setting is cost-effective when compared with PR alone in patients infected with genotype 1 HCV.
Hepatitis C
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
Natural history of hepatitis c virus infection in a cohort of asymptomatic post-transfused subjects
2012, Annals of Hepatology
Citation Excerpt :
Our data seem to support the hypothesis that mild consumption would not be associated with more rapid fibrosis in HCV infected patients.36,40 Features of present study provide a different and valuable look within the quite variable scenario on natural history of hepatitis C. On one hand, cohort studies in post-transfusional cases included patients with a history of post-transfusion hepatitis, most of them after cardiac surgery or haematological disorders.10,42-45 In our study, instead, patients were apparently healthy, asymptomatic subjects who attended a screening campaign.
Background & aims. Studies about the natural history of hepatitis C virus (HCV) infection report variable progression to cirrhosis depending on study design. Retrospective cross-sectional liver clinic studies overestimate the rate of fibrosis progression due to inclusion of patients with more severe disease leaving mild and asymptomatic patients underrepresented. We evaluated fibrosis progression in a group of “healthy” asymptomatic subjects, attending to a voluntary campaign for the detection of HCV infection.
Material and methods. A detection campaign was launched on subjects transfused before 1993. Of 1699 volunteers, 61(3.6%) had HCV infection. A liver biopsy was performed in 40 (65%). Assessed risk factors for liver fibrosis were: sex, body mass index, alcohol consumption (> 20 g/d♀ - >40g/d♂), genotype, HLA-DRB1 alleles, present age, age at infection and duration of infection.
Results. 25 (62.5%) were women with a median age of 52.5 years. The median duration of infection was 21.5 years with a median age at infection of 27 years. As regards fibrosis, 25 (62.5%) had a Low Stage (F0-F1), 8 patients, 20%, had severe fibrosis, one patient (2.5%) had cirrhosis. Alcohol consumption was the only risk factor associated with fibrosis progression.
Conclusions. The low progression to cirrhosis may be explained by the clinical characteristics of ourpopulation: asymptomatic middle-aged “healthy” subjects infected at young age. The progression to severe fibrosis was noticeable; hence a longer follow-up might demonstrate changes in this outcome. Significant alcohol consumption clearly worsens the natural history of HCV infection; this is no so evident for occasional or mild alcohol consumers.
Fibrosis in chronic viral hepatitis
2011, Best Practice and Research: Clinical Gastroenterology
In the last years, several studies have been performed with the aim to evaluate the real impact of antiviral treatments on fibrosis progression in patients with chronic viral hepatitis.
The main goal of therapy in patients with chronic hepatitis B is viral suppression. This outcome leads to an important improvement in both hepatic inflammation and fibrosis and reduces the HCC occurrence. An histological improvement has been largely demonstrated in patient treated with oral nucleoside and nucleotide analogs achieving the rate of 72% with entecavir and tenofovir.
Similarly, in patients with chronic hepatitis C, sustained virologic response to interferon therapy is associated with regression of fibrosis and lower liver decompensation and HCC occurrence.
In the next future further studies will assess the real impact of the new directly anti-viral agents on liver necroinflammation and fibrosis in chronic hepatitis C.
Optimizing choice of oral interferon-free treatment for genotype I hepatitis C virus using testing for NS5A resistance: A cost-utility analysis from the perspective of the Italian national health service
2017, ClinicoEconomics and Outcomes Research

View all citing articles on Scopus

View full text

Regular PaperLong-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

Abstract

Lancet

Lancet

Gastroenterology

Lancet

Gastroenterology

Gastroenterology

Gastroenterology

Transfusion-transmitted viruses: interim analysis of hepatitis among transfused and non-transfused patients

Prospective study of post-transfusion hepatitis in cardiac-surgery patients receiving only blood or also blood products

Vox Sang

Chronic non-A, non-B hepatitis with special reference to the transfusion-associated form

Scand J Infect Dis

Isolation of cDNA clone derived from a blood-borne non-A, non-B hepatitis genome

Science

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

Science

Hepatitis C virus: the major causative agent of viral non-A, nonB hepatitis

Br Med Bull

Post-transfusion hepatitis C in Finland

Transfus Med

The chronic sequelae of non-A, non-B hepatitis

Ann Intern Med

Regular Paper
Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis